Amogen is advancing a biosimilar candidate referencing semaglutide, one of the most widely prescribed GLP-1 receptor agonists for type 2 diabetes and obesity management. The program represents a significant milestone in Amogen's mission to expand affordable access to transformative therapies.
Semaglutide has demonstrated remarkable efficacy in clinical trials, helping patients achieve meaningful reductions in HbA1c levels and body weight. However, the high cost of originator products remains a barrier to access for millions of patients globally. Amogen's semaglutide biosimilar program offers a pathway to bridge this gap.
"Our investment in the semaglutide biosimilar program reflects Amogen's commitment to making high-quality biologic therapies accessible to patients who need them most. We believe biosimilars are essential to building a more equitable healthcare system — and our team is dedicated to delivering a product that meets the highest standards of safety, efficacy, and manufacturing quality."
Amogen's approach to developing its semaglutide biosimilar leverages deep expertise in recombinant protein expression, advanced analytical characterization, and GMP manufacturing. The company's state-of-the-art facilities are designed to support the rigorous quality requirements that biosimilar development demands.
The semaglutide biosimilar program has completed extensive physicochemical and functional comparability studies against the reference product. Preclinical data has demonstrated high similarity in mechanism of action, receptor binding affinity, and biological activity — key requirements for regulatory submissions.
As the program advances toward clinical trials, Amogen continues to invest in its peptide and biosimilar manufacturing infrastructure, positioning the company to meet growing global demand for affordable GLP-1 therapies.
For more information about Amogen's biosimilar pipeline, visit our science page.
